These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 389479)

  • 1. Potential of liposomes as drug-carriers in cancer chemotherapy: a review.
    Kaye SB; Richardson VJ
    Cancer Chemother Pharmacol; 1979; 3(2):81-5. PubMed ID: 389479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A; Shmeeda H; Barenholz Y
    Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients.
    Richardson VJ; Ryman BE; Jewkes RF; Jeyasingh K; Tattersall MN; Newlands ES; Kaye SB
    Br J Cancer; 1979 Jul; 40(1):35-43. PubMed ID: 475960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases.
    Oku N
    Biol Pharm Bull; 2017; 40(2):119-127. PubMed ID: 28154249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
    Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
    Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-selective drug delivery via folate receptor-targeted liposomes.
    Pan X; Lee RJ
    Expert Opin Drug Deliv; 2004 Nov; 1(1):7-17. PubMed ID: 16296717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal Drug Delivery Systems and Anticancer Drugs.
    Olusanya TOB; Haj Ahmad RR; Ibegbu DM; Smith JR; Elkordy AA
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29662019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of ultrasound to release chemotherapeutic drugs from micelles and liposomes.
    Ahmed SE; Martins AM; Husseini GA
    J Drug Target; 2015 Jan; 23(1):16-42. PubMed ID: 25203857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet.
    Nobuto H; Sugita T; Kubo T; Shimose S; Yasunaga Y; Murakami T; Ochi M
    Int J Cancer; 2004 Apr; 109(4):627-35. PubMed ID: 14991586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
    Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
    Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
    J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals.
    Børresen B; Hansen AE; Kjaer A; Andresen TL; Kristensen AT
    Vet Comp Oncol; 2018 Mar; 16(1):E1-E15. PubMed ID: 29027350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
    Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
    J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and use of liposomes in the treatment of microbial infections.
    Swenson CE; Popescu MC; Ginsberg RS
    Crit Rev Microbiol; 1988; 15 Suppl 1():S1-31. PubMed ID: 3293919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
    Gabizon A; Martin F
    Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-functional drug liposomes in treatment of resistant cancers.
    Mu LM; Ju RJ; Liu R; Bu YZ; Zhang JY; Li XQ; Zeng F; Lu WL
    Adv Drug Deliv Rev; 2017 Jun; 115():46-56. PubMed ID: 28433739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.